about
A decision-analytic approach to postexposure rabies prophylaxisTreatment preferences of patients and physicians: influences of summary data when framing effects are controlled.Health status, outcome, and attributability: is a red rose red in the dark?On sale: future health care. The paradox of discountingTreatment outcomes and quality of life.International differences in medical care practicesHealth values and prospect theory.Managing patients with inexplicable health problems.Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in CanadaShould patients have control over their own health care?: empirical evidence and research issues.Patient preferences for management of localized prostate cancer.Physicians in health care management: 7. The patient-physician partnership: changing roles and the desire for information.Physicians in health care management: 8. The patient-physician partnership: decision making, problem solving and the desire to participateAttitudes toward quality of survival. The concept of "maximal endurable time".Commentary on some studies on the quality of careFirst principles of cost-effectiveness analysis in health.Doctors' attitudes to risk in difficult clinical decisions: application of decision analysis in hepatobiliary diseaseAttitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general publicThe real difficulty in improving concordance of clinical practice with guidelinesDifferences in belief about likely outcomes account for differences in doctors' treatment preferences: but what accounts for the differences in belief?The Cost of Uncertain Life SpanAssessing patients' needs and preferences in the management of advanced colorectal cancer.Liver transplantation and primary biliary cirrhosisCritiques of the risk concept--valid or not?A treatment trade-off based decision aid for patients with locally advanced non-small cell lung cancer.Supporting shared decision making within the MobiGuide project.Communicating treatment effectiveness in the context of chronic disease processes.Measurement of quality of life in advanced breast cancer.Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?The realities of risk-cost-benefit analysis.Cost-effective choice of antimicrobial therapy for serious infections.Measuring and analysing quality of life in cancer clinical trials: a review.How do doctors discuss do-not-resuscitate orders?The standard gamble method: what is being measured and how it is interpreted.Cost-effectiveness analysis with risk aversion.Proportional heuristics in time tradeoff and conjoint measurement.Assigning values to intermediate health states for cost-utility analysis: theory and practice.Combined analysis identifies six genes correlated with augmented malignancy from non-small cell to small cell lung cancer.Discount functions and the measurement of patients' values. Women's decisions during childbirth.The clinical utility of utility assessment.
P2860
Q24672785-C77FAC67-DDD8-4A33-A316-B1E566965AF2Q30582470-D2852039-8EC6-4EF5-ABBE-433D3516DA34Q33553946-3BB19483-CF8E-4C6D-94DD-5172F7692D43Q33560263-8AA4903D-8A15-4EC0-9559-930908183B3BQ33626203-1952A58B-96A5-4136-B8CA-D7E22D6DCA0DQ33630125-CC8F83CF-50DC-411D-9576-7B00945BCC29Q33698546-C23A8E3F-2F81-472D-8AC5-C20D86463C15Q33814307-6F3618CC-2D23-41FA-AD01-404AE0317DB1Q34005116-6586FB94-9E9D-4A73-A1CE-6B5994641519Q34111091-DCC0C602-7F24-4091-8900-5E5EC84A93B9Q34195873-236AB27C-1ECA-4425-80D4-EBBA023C2E2EQ34276478-9766857F-A305-4F40-8195-08E7B373A770Q34277095-D4B02EF4-A350-4FB8-8E0C-FBE183FBC7DAQ34280518-C9993173-7E73-4FB2-8E08-EA130AF1C593Q34329284-7A53502F-9D04-461A-AAFA-5E9EEC18A044Q34522345-71110F37-FB97-42BE-BE4E-90FC2D91AD67Q34551095-679C5A8A-2CEE-495D-A5AA-2D40196D1CA6Q35169442-94A71738-82EA-473D-B6F3-B6E864F909DFQ35561331-0F58FDD5-B728-47AE-A685-D8B9A7177B15Q35576733-54988816-163F-4F5B-80B6-74F55A256B4BQ35774328-6E58D310-AF9A-4266-9623-6BBE35825D0FQ36291291-077D14C8-0E0E-4DFB-9CDA-75FED29744AFQ36723583-772AB33B-0348-4D88-A445-3D817F869D3EQ36939706-9AC2E58C-4B47-4ACD-B292-D68AF3508893Q37368084-E2450CC1-8759-4ED9-AEA5-466CDBBD8A64Q37508712-FC6E4EC3-06C0-4548-B499-586F82EE4019Q37763159-25326129-AFA8-4104-AD39-731A48698873Q37938331-503D02B3-4036-4147-8671-935D05889C6EQ38367507-660EFD79-B235-4EA3-B167-D0B4E464A76FQ38620088-F21882A6-24D7-42A3-A6FA-1FF607B24254Q39592533-C4F39EFA-8BBB-45B0-9A74-8DB2E6C455BCQ40173611-A8795EB3-A009-4500-BEF3-A8640F1578B1Q40356681-824738F9-CD40-469B-A68F-3958FABE0D42Q40658208-835ED7B0-F9A5-4C0F-BA1C-C86F0FB38492Q40687246-7D71A537-E99E-47DE-BF8D-39D6666FF83BQ40960060-0408E3CC-0244-46D4-B6D7-58CD7DFE0B42Q41205621-9EB07BB8-F6C6-4D78-9C42-1F7CF87E3A6AQ41389873-13735C21-08A5-4E9A-ABAD-03477DDD0C1BQ41434588-FAC393C0-D16C-4949-91AA-9A97608C385DQ41463187-8D08D3B2-F7D7-4EE0-A4CA-681C944C2393
P2860
description
1978 nî lūn-bûn
@nan
1978 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Fallacy of the five-year survival in lung cancer.
@ast
Fallacy of the five-year survival in lung cancer.
@en
Fallacy of the five-year survival in lung cancer.
@nl
type
label
Fallacy of the five-year survival in lung cancer.
@ast
Fallacy of the five-year survival in lung cancer.
@en
Fallacy of the five-year survival in lung cancer.
@nl
prefLabel
Fallacy of the five-year survival in lung cancer.
@ast
Fallacy of the five-year survival in lung cancer.
@en
Fallacy of the five-year survival in lung cancer.
@nl
P2093
P1476
Fallacy of the five-year survival in lung cancer.
@en
P2093
Weichselbaum R
P304
P356
10.1056/NEJM197812212992506
P407
P577
1978-12-01T00:00:00Z